In high-risk patients with COVID-19, nirmatrelvir/ritonavir treatment shortened the median duration to return to usual health and activities and significantly accelerated the resolution of COVID-19 ...
Nirmatrelvir–ritonavir has been shown to reduce progression to severe illness from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in unvaccinated high-risk outpatients. The effectiveness ...
Two multicenter trials found no change in hospitalization and death rates when antiviral nirmatrelvir-ritonavir (Paxlovid) was given to COVID-19 patients already mostly vaccinated. However, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results